[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560154":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":40,"studyPopulation":43,"armGroups":44,"interventions":74,"overallOfficials":40,"centralContacts":79,"locations":85,"responsibleParty":103,"collaborators":40,"id":105,"slug":40,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":40,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":118,"studyType":119,"phases":40,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":88,"whyStopped":40,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Henan University of Traditional Chinese Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":40},[9,13,16,19,22],{"measure":10,"description":11,"timeFrame":12},"Interleukin-2、4、5、13 (IL-2、4、5、13)","Airway inflammation will be assessed using the IL-2、4、5、13.","Basline",{"measure":14,"description":15,"timeFrame":12},"Interferon-γ (IFN-γ)","Airway inflammation will be assessed using the IFN-γ.",{"measure":17,"description":18,"timeFrame":12},"Tumor necrosis factor-β (TNF-β)","Airway inflammation will be assessed using the TNF-β.",{"measure":20,"description":21,"timeFrame":12},"Eosinophil cationic proteins (ECP)","Airway inflammation will be assessed using the ECP.",{"measure":23,"description":24,"timeFrame":12},"Immunoglobulin E (IgE)","Airway inflammation will be assessed using the IgE.",[26,29,32,34,37],{"measure":27,"description":28,"timeFrame":12},"Fractional exhaled nitric oxide (FeNO)","Higher FeNO values indicate higher airway inflammation.",{"measure":30,"description":31,"timeFrame":12},"Forced expiratory volume in one second (FEV1)","Lung function will be assessed using the FEV1.",{"measure":33,"description":31,"timeFrame":12},"Forced vital capacity (FVC)",{"measure":35,"description":36,"timeFrame":12},"FVC as the percentage of the predicted value (FVC%)","Lung function will be assessed using the FVC%.",{"measure":38,"description":39,"timeFrame":12},"Forced expiratory volume in one second \u002F forced vital capacity (FEV1\u002FFVC)","Lung function will be assessed using the FEV1\u002FFVC.",null,{"allocation":40,"interventionModel":40,"interventionModelDescription":40,"primaryPurpose":40,"observationalModel":6,"timePerspective":42,"maskingInfo":40},"CROSS_SECTIONAL","Allergic rhinitis (AR) is a common chronic inflammatory disease of the upper respiratory tract with paroxysmal sneezing, nasal congestion, watery nasal discharge and nasal itching as the main clinical symptoms. Bronchial asthma (BA) is a complex heterogeneous chronic inflammatory disease of the bronchi with recurrent symptoms of wheezing, shortness of breath, chest tightness, and coughing.AR usually coexists with BA, and about 70-90% of patients with asthma develop rhinitis, and about 40% of patients with rhinitis develop asthma. When AR and BA occur together, it is called combined allergic rhinitis and asthma syndrome (CARAS).",[45,50,53,56,59,62,65,68,71],{"label":46,"type":40,"description":47,"interventionNames":48},"acute exacerbation CARAS","Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.",[49],"Other: questionnaire survey",{"label":51,"type":40,"description":47,"interventionNames":52},"chronic persistence CARAS",[49],{"label":54,"type":40,"description":47,"interventionNames":55},"clinical control CARAS",[49],{"label":57,"type":40,"description":47,"interventionNames":58},"acute exacerbation BA",[49],{"label":60,"type":40,"description":47,"interventionNames":61},"chronic persistence BA",[49],{"label":63,"type":40,"description":47,"interventionNames":64},"clinical control BA",[49],{"label":66,"type":40,"description":47,"interventionNames":67},"intermittent AR",[49],{"label":69,"type":40,"description":47,"interventionNames":70},"persistent AR",[49],{"label":72,"type":40,"description":47,"interventionNames":73},"healthy individuals",[49],[75],{"type":6,"name":76,"description":77,"armGroupLabels":78,"otherNames":40},"questionnaire survey","subjects fill out questionnaires",[57,46,60,51,63,54,72,66,69],[80],{"name":81,"role":82,"phone":83,"phoneExt":40,"email":84},"Yang Xie","CONTACT","13526621325","xieyanghn@163.com",[86],{"facility":87,"status":88,"city":89,"state":90,"zip":40,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"The First Affiliated Hospital of Henan University of Chinese Medicine","RECRUITING","Henan","Zhengzhou","China","CN",{"type":94,"coordinates":95},"Point",[96,97],112.22494,37.92189,{"lat":97,"lon":96},[100],{"name":101,"role":82,"phone":102,"phoneExt":40,"email":84},"Yang Xie, Ph.D","+8613526621325",{"type":104,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100560154",false,"NCT06573450","Exhaled Breath Condensate Biomarkers in CARAS","Preliminary Application and Evaluation of Exhaled Breath Condensate Biomarkers in Combined Allergic Rhinitis and Asthma Syndrome (CARAS)","Inclusion Criteria:\n\n* Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria;\n* Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence;\n* Age 18 to 80 years;\n* Voluntarily accepted the study and signed an informed consent form;\n* Not participated in other clinical studies within 1 month before enrollment.\n\nExclusion Criteria:\n\n* Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose;\n* Patients who are participating in other drug trials;\n* Patients with a combination of other serious systemic diseases;\n* Pregnant or lactating women;\n* Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.",true,"ALL","18 Years","80 Years",{"count":116,"type":117},270,"ESTIMATED","1 Day","OBSERVATIONAL","To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.",[122],"Combined Allergic Rhinitis and Asthma Syndrome",[124,125,126,127],"CARAS","EBC","Biomarkers","Combination of disease and evidence","2024-08-27",{"date":130,"type":131},"2024-08-28","ACTUAL",{"date":133,"type":131},"2023-04-01",{"date":135,"type":117},"2025-05-30",{"name":5,"class":6},1]